Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sanofi : Swung to 4Q Loss; Dupixent Drives Sales Higher

share with twitter share with LinkedIn share with facebook
share via e-mail
02/06/2020 | 01:45am EDT

By Carlo Martuscelli

Sanofi SA (SAN.FR) swung to a net loss in its fourth quarter results Thursday after booking impairment charges on a number of its assets, but reported rising sales on the back of a strong performance from Dupixent--a treatment for eczema and other allergic diseases.

The French pharmaceutical major posted a net loss of 10 million euros ($11 million), compared with a profit of EUR254 million for the year-before period, while sales increased by 6.1% to EUR9.61 billion.

Business net income--a company metric watched by analysts--grew 24% to EUR1.68 billion, ahead of a consensus analyst forecast of EUR1.36 billion as provided by FactSet.

Dupixent, a monoclonal antibody used to treat allergic diseases such as eczema and nasal polyps, generated quarterly sales of EUR679 million, more than double than the year before. The company said its vaccine division also performed well, with sales from the unit increasing by 22% thanks to influenza vaccine shipments in the U.S.

Sanofi reported EUR1.58 billion in impairments in the quarter, a sharp rise from the year before, relating to Eloctate and Zantac.

Looking ahead, the drug maker guided business earnings per share growth of 5% at constant exchange rates in 2020.

Sanofi also reported positive results from a phase 2 study of its BTKI inhibitor in multiple sclerosis. Data showed that the investigational drug--characterized by its ability to cross the blood-brain barrier--was able to significantly reduce disease activity. The treatment, called SAR442168, will be taken to phase 3 trial, Sanofi said.

Write to Carlo Martuscelli at carlo.martuscelli@wsj.com; @carlomartu

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SANOFI
06:37aREGENERON PHARMACEUTICALS : First patient outside U.S. treated in global Kevzara..
AQ
06:36aSANOFI : - First patient outside U.S. treated in global Kevzara clinical trial p..
AQ
03/30Postponement of Annual General Meeting of Sanofi - Aventis Pakistan Limited
AQ
03/30SANOFI : receives positive CHMP opinion for Sarclisa for the treatment of relaps..
AQ
03/30SANOFI : Pasteur and Translate Bio to Collaborate to Develop a Novel mRNA Vaccin..
AQ
03/30REGENERON PHARMACEUTICALS : Sanofi, Regeneron expand testing of potential corona..
RE
03/30SANOFI : First patient outside U.S. treated in global Kevzara® (sarilumab) clini..
GL
03/27TRANSLATE BIO : Shares Gain After FDA Grants Rare Pediatric Disease Designation
DJ
03/27SANOFI : Translate Bio to Develop Covid-19 Vaccine Candidate
DJ
03/27SANOFI : receives positive CHMP opinion for Sarclisa® (isatuximab) for the treat..
GL
More news
Financials (EUR)
Sales 2019 36 409 M
EBIT 2019 9 632 M
Net income 2019 3 910 M
Debt 2019 15 066 M
Yield 2019 3,92%
P/E ratio 2019 26,6x
P/E ratio 2020 18,9x
EV / Sales2019 3,17x
EV / Sales2020 3,05x
Capitalization 100 B
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 100,18  €
Last Close Price 80,14  €
Spread / Highest target 42,3%
Spread / Average Target 25,0%
Spread / Lowest Target -0,17%
EPS Revisions
Managers
NameTitle
Paul Hudson Chief Executive Officer & Director
Serge Weinberg Chairman
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Ameet Nathwani Chief Medical & Digital Officer
John C. Reed EVP & Global Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-10.58%111 121
JOHNSON & JOHNSON-8.82%350 661
ROCHE HOLDING AG-5.53%273 496
MERCK & CO., INC-15.40%195 166
NOVARTIS-17.30%183 669
PFIZER, INC.-16.69%181 241